• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·LLY
Held by 4 Gurus
Share

Eli Lilly and Company Stocks

$ 1209.85Last Updated 13.08.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Low

Recommendation

Hold

Market Cap

$ 1.15T

$ 1209.85
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.5%

Change

-0.29%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.3%

Change

-0.00%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.2%

Change

-0.04%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.5%-0.29%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.3%-0.00%
Steven CohenPoint72 Asset Management, L.P.0.2%-0.04%
Show more

Latest news

05.08.2026 23:41

Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline

05.08.2026 15:41

Morning in New York: Market News Will Exacerbate Volatility

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

24.07.2026 14:59

IPO Scribe: Shares in a biotech company backed by Eli Lilly and Sanofi are now available

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of LLY is 1320 and suggests 9.09% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

15.08.2026 02:58

Shares of U.S. drone manufacturers surged following Trump's new tariffs

15.08.2026 02:44

The market is unfazed by the stock decline: Wall Street's fear index is at its lowest level since December

15.08.2026 01:23

Applied Materials shares fell following the earnings report. Analysts advise taking advantage of this opportunity

15.08.2026 00:09

A 10% Plunge or a New Rally: BofA Outlines Scenarios for Stocks After the U.S. Election

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026